Windlas Biotech Limited - Asset Resilience Ratio

Latest as of September 2025: 32.06%

Windlas Biotech Limited (WINDLAS) has an Asset Resilience Ratio of 32.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Windlas Biotech Limited balance sheet assets for the complete picture of this company's asset base.

Liquid Assets

Rs2.61 Billion
≈ $28.23 Million USD Cash + Short-term Investments

Total Assets

Rs8.14 Billion
≈ $88.05 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Windlas Biotech Limited's Asset Resilience Ratio has changed over time. See WINDLAS equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Windlas Biotech Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Windlas Biotech Limited market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs2.61 Billion 32.06%
Total Liquid Assets Rs2.61 Billion 32.06%

Asset Resilience Insights

  • Very High Liquidity: Windlas Biotech Limited maintains exceptional liquid asset reserves at 32.06% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Windlas Biotech Limited Industry Peers by Asset Resilience Ratio

Compare Windlas Biotech Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Ajanta Pharma Limited
NSE:AJANTPHARM
Drug Manufacturers - Specialty & Generic 14.99%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
Drug Manufacturers - Specialty & Generic 2.09%
Dezhan HealthCare Co Ltd
SHE:000813
Drug Manufacturers - Specialty & Generic 0.15%

Annual Asset Resilience Ratio for Windlas Biotech Limited (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Windlas Biotech Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 31.54% Rs2.40 Billion
≈ $25.94 Million
Rs7.60 Billion
≈ $82.24 Million
-0.25pp
2024-03-31 31.79% Rs1.99 Billion
≈ $21.53 Million
Rs6.26 Billion
≈ $67.72 Million
+7.54pp
2023-03-31 24.25% Rs1.28 Billion
≈ $13.87 Million
Rs5.29 Billion
≈ $57.21 Million
-11.48pp
2022-03-31 35.73% Rs1.75 Billion
≈ $18.97 Million
Rs4.91 Billion
≈ $53.10 Million
+22.79pp
2021-03-31 12.94% Rs383.25 Million
≈ $4.14 Million
Rs2.96 Billion
≈ $32.02 Million
+6.27pp
2020-03-31 6.67% Rs225.86 Million
≈ $2.44 Million
Rs3.38 Billion
≈ $36.61 Million
-0.45pp
2019-03-31 7.12% Rs212.41 Million
≈ $2.30 Million
Rs2.98 Billion
≈ $32.25 Million
-0.76pp
2018-03-31 7.88% Rs228.53 Million
≈ $2.47 Million
Rs2.90 Billion
≈ $31.35 Million
--
pp = percentage points

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic
Market Cap
$186.84 Million
Rs17.28 Billion INR
Market Cap Rank
#16896 Global
#871 in India
Share Price
Rs819.70
Change (1 day)
-0.38%
52-Week Range
Rs718.35 - Rs1070.80
All Time High
Rs1144.25
About

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more